Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors

NCT04429542 is registered in ClinicalTrials.gov with Bicara Therapeutics as lead sponsor.

NCT NCT04429542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04429542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Lead sponsor
Bicara Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2020
Completion date
March 30, 2028
Enrollment
473 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell, colorectal cancer, cutaneous squamous cell carcinoma, egfr amplification, epithelial ovarian cancer, head and neck neoplasms, head and neck squamous cell carcinoma, pancreas cancer, squamous cell carcinoma of anal canal, squamous cell carcinoma of head and neck, squamous cell carcinoma of the lung